JP2017537888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537888A5 JP2017537888A5 JP2017522654A JP2017522654A JP2017537888A5 JP 2017537888 A5 JP2017537888 A5 JP 2017537888A5 JP 2017522654 A JP2017522654 A JP 2017522654A JP 2017522654 A JP2017522654 A JP 2017522654A JP 2017537888 A5 JP2017537888 A5 JP 2017537888A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fusion protein
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 42
- 102000037240 fusion proteins Human genes 0.000 claims 30
- 108020001507 fusion proteins Proteins 0.000 claims 30
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 claims 16
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 16
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102000018358 Immunoglobulins Human genes 0.000 claims 6
- 108060003951 Immunoglobulins Proteins 0.000 claims 6
- 200000000018 inflammatory disease Diseases 0.000 claims 6
- 239000003001 serine protease inhibitor Substances 0.000 claims 6
- 201000009910 diseases by infectious agent Diseases 0.000 claims 5
- 102100001249 ALB Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 101710027066 ALB Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 229940050528 albumin Drugs 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010060945 Bacterial infection Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 230000001594 aberrant Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000003883 cystic fibrosis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001263 psoriatic arthritis Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/524,832 | 2014-10-27 | ||
| US14/524,832 US10400029B2 (en) | 2011-06-28 | 2014-10-27 | Serpin fusion polypeptides and methods of use thereof |
| PCT/US2015/057533 WO2016069574A1 (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121953A Division JP2020180157A (ja) | 2014-10-27 | 2020-07-16 | セルピン融合ポリペプチド及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537888A JP2017537888A (ja) | 2017-12-21 |
| JP2017537888A5 true JP2017537888A5 (sl) | 2018-10-25 |
| JP6737781B2 JP6737781B2 (ja) | 2020-08-12 |
Family
ID=55858243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522654A Active JP6737781B2 (ja) | 2014-10-27 | 2015-10-27 | セルピン融合ポリペプチド及びその使用方法 |
| JP2020121953A Pending JP2020180157A (ja) | 2014-10-27 | 2020-07-16 | セルピン融合ポリペプチド及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121953A Pending JP2020180157A (ja) | 2014-10-27 | 2020-07-16 | セルピン融合ポリペプチド及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3212290A4 (sl) |
| JP (2) | JP6737781B2 (sl) |
| KR (2) | KR20170091096A (sl) |
| CN (2) | CN107206257A (sl) |
| AU (3) | AU2015339507B2 (sl) |
| BR (1) | BR112017008525A2 (sl) |
| CA (1) | CA2965151A1 (sl) |
| HK (1) | HK1244460A1 (sl) |
| IL (2) | IL251799B2 (sl) |
| MX (2) | MX2017005467A (sl) |
| RU (1) | RU2746550C2 (sl) |
| SG (2) | SG10201903142RA (sl) |
| UA (1) | UA127305C2 (sl) |
| WO (1) | WO2016069574A1 (sl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210388059A1 (en) * | 2018-10-29 | 2021-12-16 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| CN111989340A (zh) * | 2018-11-18 | 2020-11-24 | 杭州博虎生物科技有限公司 | 一种重组人白细胞介素10融合蛋白及其应用 |
| CN112315897A (zh) * | 2020-11-04 | 2021-02-05 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法 |
| US20240067703A1 (en) * | 2020-12-21 | 2024-02-29 | Macquarie University | Treatment of glaucoma |
| GB202102258D0 (en) | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
| US20240139296A1 (en) * | 2021-03-03 | 2024-05-02 | Formycon Ag | Formulations of ace2 fc fusion proteins |
| CN113325181A (zh) * | 2021-04-25 | 2021-08-31 | 苏州市立医院(北区) | 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用 |
| CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| WO2023225513A1 (en) | 2022-05-16 | 2023-11-23 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2364471A1 (en) * | 1999-03-01 | 2000-09-08 | Human Genome Sciences, Inc. | Human serpin proteins |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CN1852920B (zh) * | 2003-07-18 | 2010-12-15 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
| CA2536918A1 (en) * | 2003-08-26 | 2005-03-03 | Leland Shapiro | Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules |
| AU2005304624B2 (en) * | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| WO2007021807A1 (en) * | 2005-08-12 | 2007-02-22 | Schering Corporation | Mcp1 fusions |
| WO2009158432A2 (en) * | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| BRPI0918122A8 (pt) * | 2008-12-19 | 2017-01-24 | Macrogenics Inc | molécula de diabody, diabody, e mólecula dart |
| CA2822366A1 (en) * | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| ES2692268T3 (es) * | 2011-03-29 | 2018-12-03 | Roche Glycart Ag | Variantes de Fc de anticuerpo |
| EP2726093A4 (en) * | 2011-06-28 | 2015-08-19 | Inhibrx Llc | WAP DOMAIN FUSION POLYPEPTIDES AND METHOD FOR THEIR USE |
| AU2012275287B2 (en) * | 2011-06-28 | 2017-10-05 | Inhibrx, Inc. | Serpin fusion polypeptides and methods of use thereof |
| JP2015504675A (ja) * | 2012-01-10 | 2015-02-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用 |
| CN104582736A (zh) * | 2012-06-21 | 2015-04-29 | 印第安纳大学研究及科技有限公司 | Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物 |
| CA2871882A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| PL2880170T3 (pl) * | 2012-08-02 | 2017-02-28 | F.Hoffmann-La Roche Ag | SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA |
| JP6345688B2 (ja) * | 2012-12-05 | 2018-06-20 | ソラ・バイオサイエンシズ・エルエルシー | タンパク質発現増強ポリペプチド |
-
2015
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/ja active Active
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/ru active
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 UA UAA201705128A patent/UA127305C2/uk unknown
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/pt active Search and Examination
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/ko not_active IP Right Cessation
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/zh active Pending
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/es unknown
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en active Application Filing
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/ko active Application Filing
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/zh active Pending
-
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/es unknown
-
2018
- 2018-03-05 HK HK18103148.5A patent/HK1244460A1/zh unknown
-
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/ja active Pending
-
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en not_active Abandoned
-
2024
- 2024-05-29 AU AU2024203586A patent/AU2024203586A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537888A5 (sl) | ||
| HRP20191652T1 (hr) | Fuzijski polipeptidi na bazi serpina i postupci za njihovu uporabu | |
| RU2017118325A (ru) | Слитые серпиновые полипептиды и способы их применения | |
| JP6920230B2 (ja) | アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物 | |
| JP2022043042A5 (sl) | ||
| JP2020171316A (ja) | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 | |
| JP2018070625A5 (sl) | ||
| JP2010524971A5 (sl) | ||
| JP5600061B2 (ja) | α−１−抗トリプシンおよびアポリポタンパク質Ａ−Ｉを精製する方法 | |
| JP6923115B2 (ja) | 高グリコシル化ヒト血液凝固第ｖｉｉｉ因子の融合タンパク質、その調製方法、および使用 | |
| JP2008507298A5 (sl) | ||
| JP2015504675A5 (sl) | ||
| JP2020534865A5 (sl) | ||
| CN113173995B (zh) | 一种结合冠状病毒的双特异性抗体 | |
| JP2017500035A5 (sl) | ||
| JP2003530093A5 (sl) | ||
| JP6938565B2 (ja) | Ｕｔｉ融合タンパク質 | |
| JP2007509984A5 (sl) | ||
| JP2009507503A5 (sl) | ||
| RU2014102585A (ru) | Слитые полипептиды, содержащие домен wap, и способы их применения | |
| JP2020019813A5 (sl) | ||
| CA2806438A1 (en) | Chimeric il-1 receptor type i agonists and antagonists | |
| WO2018154044A1 (en) | Modified serpins for the treatment of bradykinin-mediated disease | |
| WO2003062370B1 (en) | Multimeric proteins and methods of making and using same | |
| WO2012048653A1 (zh) | 干扰素-白蛋白结合肽的融合蛋白及其用途 |